
Current Price | $0.18 | Mkt Cap | $16.4M |
---|---|---|---|
Open | $0.17 | P/E Ratio | -0.38 |
Prev. Close | $0.18 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.16 - $0.18 | Volume | 450,968 |
52-Wk Range | $0.12 - $1.76 | Avg. Daily Vol. | 863,076 |
The Company's mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions.
Current Price | $0.18 | Mkt Cap | $16.4M |
---|---|---|---|
Open | $0.17 | P/E Ratio | -0.38 |
Prev. Close | $0.18 | Div. (Yield) | $0.00 (0.0%) |
Daily Range | $0.16 - $0.18 | Volume | 450,968 |
52-Wk Range | $0.12 - $1.76 | Avg. Daily Vol. | 863,076 |
The best Bull and Bear pitches based on recency and number of recommendations.
http://www.fool.com/investing/general/2011/07/15/3-stocks-near-52-week-highs-worth-selling.aspx
Read the most recent pitches from players about INFI.
Recs
Infinity Pharmaceuticals Earns $22 Million Payment From Verastem Oncology For FDA Approval Of COPIKTRA™ (duvelisib) And Updates 2018 Financial Guidance
PR Newswire PR Newswire•October 1, 2018
CAMBRIDGE, Mass., Oct. 1, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (INFI) announced today that it earned a $22 million payment from Verastem Oncology under the license agreement between the Company and Verastem for COPIKTRA (duvelisib). The payment was earned upon the approval by the U.S. Food and Drug Administration (FDA) on September 24, 2018 of duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies, as well as accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies.
"We are really pleased that duvelisib is now available for patients with CLL/SLL and follicular lymphoma and are proud of the role Infinity played in its development," said Adelene Perkins, Chief Executive Officer and Chair of Infinity. "This $22 million FDA approval payment from Verastem supports Infinity's continued expansion of the development of IPI-549, our first-in-class, oral, immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma), including in doublet and triplet combination trials to identify the best combination regimens to treat patients with specific types of cancer."
In 2016, Infinity entered into a license agreement granting Verastem an exclusive worldwide license for the research, development, commercialization, and manufacture of duvelisib and products containing duvelisib in oncology. Pursuant to the terms of the license agreement, Verastem has notified Infinity of its election to make the $22 million payment in cash, which Infinity expects to receive later this year. Infinity also is eligible for royalties on worldwide net sales of duvelisib ranging from the mid-to-high single digits, shared equally with Takeda.
Recs
nev
Recs
Oversold.
Find the members with the highest scoring picks in INFI.
Zippidy3 (33.22) Score: +433.34
The Score Leader is the player with the highest score across all their picks in INFI.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
Zippidy3 | 33.22 | 7/28/2009 |
![]() |
5Y | $8.48 | -97.85% | +335.48% | +433.34 | 0 Comment | |
KeepYourCoolFool | 95.72 | 7/29/2009 |
![]() |
5Y | $8.69 | -97.90% | +334.42% | +432.32 | 0 Comment | |
whoitis | 71.58 | 7/28/2009 |
![]() |
NS | $8.06 | -97.74% | +333.97% | +431.71 | 0 Comment | |
SpencerHar | < 20 | 8/3/2009 |
![]() |
3Y | $8.07 | -97.74% | +324.78% | +422.52 | 0 Comment | |
WallStreetRafael | < 20 | 9/1/2010 |
![]() |
5Y | $4.98 | -96.34% | +289.67% | +386.02 | 0 Comment | |
longtermgrowth09 | 51.07 | 12/17/2009 |
![]() |
5Y | $5.63 | -96.77% | +280.98% | +377.74 | 0 Comment | |
mdicksonjr | 30.05 | 5/21/2012 |
![]() |
5Y | $12.49 | -98.54% | +224.08% | +322.62 | 0 Comment | |
vjport | 74.41 | 5/23/2012 |
![]() |
1Y | $12.27 | -98.52% | +221.39% | +319.90 | 0 Comment | |
storkk | < 20 | 6/12/2012 |
![]() |
5Y | $12.47 | -98.54% | +220.07% | +318.61 | 0 Comment | |
ANDRZEJ38 | 45.48 | 4/8/2008 |
![]() |
5Y | $7.30 | -97.51% | +221.09% | +318.60 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.